CHEK2 gene

Associated Syndrome Name: CHEK2-associated Cancer Risk

**CHEK2 Summary Cancer Risk Table**

<table>
<thead>
<tr>
<th>CANCER</th>
<th>GENETIC CANCER RISK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>High Risk</td>
</tr>
<tr>
<td>Male Breast</td>
<td>Elevated Risk</td>
</tr>
<tr>
<td>Colorectal</td>
<td>Elevated Risk</td>
</tr>
</tbody>
</table>

**CHEK2 gene Overview**

**CHEK2-associated Cancer Risk**

1. Women with CHEK2 mutations have a risk for breast cancer that is significantly increased over the 12.5% lifetime risk for women in the general population of the United States. Men with CHEK2 mutations also have an increased risk for breast cancer.
2. Estimates of cancer risk for men and women with CHEK2 mutations vary widely and are strongly influenced by family history. In cases where there is no family history of one of these cancers, the risk for a patient with a CHEK2 mutation may be lower than in cases where that cancer has been diagnosed in one or more close relatives. Therefore, the family history of a patient should be considered when deciding on the most appropriate strategies to manage cancer risk, with more aggressive strategies targeted to patients with significant family histories of related cancers.
3. Individuals with CHEK2 mutations may have an elevated risk for colorectal cancer, and the National Comprehensive Cancer Network (NCCN) has provided screening recommendations to address this possible risk.
4. Although many different CHEK2 mutations have been identified, estimated cancer risks for CHEK2 are currently based largely on studies of a single mutation (c.1100del) that is common in patients of European ancestry. These estimates may be modified as we learn more about other CHEK2 mutations in patients of varied ancestries.
5. Some studies have described a possible increased risk for a wide range of cancers in patients with CHEK2 mutations, including prostate, leukemia, lymphoma, gastric cancer, thyroid cancer and other malignancies. However, these studies are not conclusive and there are currently no medical management guidelines to address these possible risks.
6. Although there are increased risks for cancer in men and women with mutations in CHEK2, there are interventions that may reduce these risks. Guidelines from the National Comprehensive Cancer Network (NCCN) that may apply are listed below. Since information about the cancer risks associated with CHEK2 mutations is relatively new, and there is still some uncertainty about the best ways to reduce these risks, it may be appropriate to interpret these results in consultation with cancer genetics experts in this emerging area of knowledge.

**CHEK2 gene Cancer Risk Table**

<table>
<thead>
<tr>
<th>CANCER TYPE</th>
<th>AGE RANGE</th>
<th>CANCER RISK</th>
<th>RISK FOR GENERAL POPULATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>To age 801, 2, 3, 4</td>
<td>23%-48%</td>
<td>10.2%</td>
</tr>
</tbody>
</table>

1. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
## CHEK2 Cancer Risk Management Table

The overview of medical management options provided is a summary of professional society guidelines as of the last Myriad update shown on this page. The specific reference provided (e.g., NCCN guidelines) should be consulted for more details and up-to-date information before developing a treatment plan for a particular patient. This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient’s personal medical history, surgeries and other treatments.

<table>
<thead>
<tr>
<th>CANCER TYPE</th>
<th>AGE RANGE</th>
<th>CANCER RISK</th>
<th>RISK FOR GENERAL POPULATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Breast</td>
<td>Second primary within 10 years of first breast cancer diagnosis$^10$</td>
<td>Up to 29%</td>
<td>4.0%</td>
</tr>
<tr>
<td>Male Breast</td>
<td>To age 80$^6$</td>
<td>0.4%-1%</td>
<td>0.1%</td>
</tr>
<tr>
<td>Colorectal</td>
<td>To age 80$^8$</td>
<td>Possibly elevated risk</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

**Information for Family Members**
The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the CHEK2 gene.

A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions.

References


Last Updated on 07-Nov-2018